Patents Examined by Rei Tsang Shiao
  • Patent number: 12285425
    Abstract: Methods for treating a subject having a cancerous tumor are disclosed. The methods comprise administering to the subject an effective amount of a non-steroidal selective glucocorticoid receptor modulator (SGRM) and an effective amount of a chemotherapeutic agent. The tumor may be cervical cancer. The SGRM may be a fused azadecalin. In embodiments, the SGRM may be a heteroaryl ketone fused azadecalin or an octahydro fused azadecalin.
    Type: Grant
    Filed: April 18, 2023
    Date of Patent: April 29, 2025
    Assignee: Corcept Therapeutics, Inc.
    Inventor: Hazel Hunt
  • Patent number: 12280034
    Abstract: A method for lowering systolic blood pressure in a patient exhibiting resistance to a antihypertensive therapy with one or more drugs, the method comprising administering to the patient ANAVEX®2-73 at a dose and frequency effective to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, 24-hour ambulatory systolic, and maximum diurnal systolic blood pressures.
    Type: Grant
    Filed: November 14, 2022
    Date of Patent: April 22, 2025
    Assignee: Anavex Life Sciences Corp.
    Inventor: Christopher U. Missling
  • Patent number: 12281087
    Abstract: Ebselen analogue compounds, their synthesis, and nanoemulsions containing the same. The nanoemulsions can comprise the ebselen analogue, tea tree oil, Tween, and water.
    Type: Grant
    Filed: January 22, 2024
    Date of Patent: April 22, 2025
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Manal Amin Hessein, Saad Shaaban
  • Patent number: 12280038
    Abstract: Described herein are novel ?- and ?-propargyl carboxylic acids and esters. The novel compositions are antagonists of CSE and may be used to modulate of the activity of the carotid body, therefore providing therapeutic benefits for sleep-related breathing disorders and related conditions.
    Type: Grant
    Filed: June 24, 2022
    Date of Patent: April 22, 2025
    Assignees: The University of Chicago, IIT Research Institute
    Inventors: Michael J. Kates, Nanduri R. Prabhakar, David L. McCormick, Miguel Muzzio
  • Patent number: 12274706
    Abstract: Disclosed is a new pharmaceutical composition for oral administration containing sulfasalazine and/or a sulfasalazine organic salt, production processes and uses, in particular in the treatment of a disease or condition in which modulation of inflammatory cells is beneficial, a disease or condition concerning bones or joints and/or the gastro-intestinal tract.
    Type: Grant
    Filed: May 23, 2023
    Date of Patent: April 15, 2025
    Assignee: MEDAC GESELLSCHAFT FUER KLINISCHE
    Inventors: Marguerite Mensonides-Harsema, Sebastian Bialleck, Sonja Schuldt-Lieb
  • Patent number: 12268218
    Abstract: Methods for inoculating a grain suitable for use in testing methods of reducing bacterial load are disclosed. Also disclosed are methods of reducing bacterial load on a grain by using elevated temperature and an organic acid. Also disclosed are methods of tempering a grain at an elevated temperature and reduced time as compared to standard tempering methods.
    Type: Grant
    Filed: February 7, 2023
    Date of Patent: April 8, 2025
    Assignee: General Mills, Inc.
    Inventors: David J. Domingues, Steven R. Pretzel, Yuewei Hu, Craig A. Dowd, James P. Michaels
  • Patent number: 12269815
    Abstract: The disclosure is directed to dantrolene prodrugs, compositions thereof, and methods of their use in the treatment of disease.
    Type: Grant
    Filed: May 24, 2022
    Date of Patent: April 8, 2025
    Assignee: Eagle Research Labs Limited
    Inventors: Charles Wescott, Adrian Hepner, Alyssa Larson
  • Patent number: 12263146
    Abstract: The present disclosure relates to methods for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by administering to a patient in need thereof mirdametinib or a pharmaceutically acceptable salt thereof, such as by a certain dosing scheme.
    Type: Grant
    Filed: August 2, 2023
    Date of Patent: April 1, 2025
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Uchenna H. Iloeje, Abraham J. Langseth, Todd Shearer
  • Patent number: 12263173
    Abstract: Provided include methods, compositions and kits for treating metastatic cancer in a subject. The method can comprise administrating a treatment comprising inhibiting angiogenesis and a PLK1 inhibitor (for example, onvansertib) to the subject that has not received prior anti-angiogenic treatment, in a manner sufficient to reduce or inhibit progression of the metastatic cancer.
    Type: Grant
    Filed: June 21, 2024
    Date of Patent: April 1, 2025
    Assignee: Cardiff Oncology, Inc.
    Inventors: Maya Ridinger, Mark Erlander
  • Patent number: 12263158
    Abstract: A tizanidine liquid preparation and use of the tizanidine liquid preparation in the preparation of a medicament for treating muscle spasm, wherein the tizanidine liquid preparation comprises an active ingredient, disodium EDTA and other pharmaceutical excipients, wherein the active ingredient is one or more of tizanidine or a pharmaceutically acceptable salt, solvate and hydrate thereof.
    Type: Grant
    Filed: May 7, 2022
    Date of Patent: April 1, 2025
    Assignee: FIDELITY BIOPHARMA CO.
    Inventors: Gang Chen, Gongzheng Chen, Song Lin, Rashmi Rohit Prasade, Ganesh Dattatray Chavan Patil
  • Patent number: 12257257
    Abstract: Disclosed is a method and oral composition for treating a plurality of End stage diseases such as end-stage renal disease, chronic kidney disease, liver cirrhosis, chronic liver failure, end stage liver disease, Cancer, congestive Heart failure, pulmonary fibrosis, chronic obstructive pulmonary disease. In an embodiment of the invention, the composition comprises testosterone duodecanoate.
    Type: Grant
    Filed: May 3, 2024
    Date of Patent: March 25, 2025
    Inventors: Mahesh V. Patel, Kongnara Papangkorn, Jonathan Ogle, Nachiappan Chidambaram, Benjamin J. Bruno
  • Patent number: 12251368
    Abstract: A method of treating patients by using a pharmaceutical composition for intra-intestinal administration comprises (i) a dopamine replacement agents, (ii) a dopamine decarboxylase inhibitor (DDI), and (iii) a COMT inhibitor where the composition is continuously administered.
    Type: Grant
    Filed: November 4, 2022
    Date of Patent: March 18, 2025
    Assignee: InTrance Medical Systems Inc.
    Inventor: Roger Bolsöy
  • Patent number: 12239645
    Abstract: The dosages and methods described herein provide desirable pharmacokinetic (PK) and pharmacodynamics (PD) characteristics which inhibit alternative pathway complement activity, for example at least 85% or more inhibition of AP activity in vivo at dosages from about 120 mg to 200 mg BID that provides a plasma level Ctrough at least about 65 ng/ml, which provides sufficient AP inhibition to reduce the risk of complement breakthrough. In addition, the dosage form described herein provides a significantly low Cmax, providing additional safety margin and better dosing flexibility.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: March 4, 2025
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Mingjun Huang, Steven D. Podos
  • Patent number: 12239621
    Abstract: One object of the present invention is to provide an inhibitor for renal injuries induced by a hemolytic reaction. In this invention, cilastatin or a pharmaceutically acceptable salt thereof is used.
    Type: Grant
    Filed: March 8, 2022
    Date of Patent: March 4, 2025
    Assignees: Niigata University, Denka Company Limited
    Inventors: Akihiko Saito, Sawako Goto, Yoshiaki Hirayama
  • Patent number: 12239637
    Abstract: The present invention generally relates to compositions and methods for treating a neurological disorder in a subject, the method including administering to the subject in need of such treatment a composition including a therapeutically effective amount of a CCR5 antagonist. The CCR5 antagonist may be, for example, maraviroc. The neurological disorder may be, for example, Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies or multiple system atrophy.
    Type: Grant
    Filed: October 18, 2022
    Date of Patent: March 4, 2025
    Assignee: RUSH UNIVERSITY MEDICAL CENTER
    Inventor: Kalipada Pahan
  • Patent number: 12239614
    Abstract: Methods for prophylactically treating a stress-induced affective disorder or stress-induced psychopathology in a subject are provided. Also provided are methods for inducing and/or enhancing stress resilience in a subject. In certain embodiments, an effective amount of (R,S)-ketamine or (2R,6R)-hydroxynorketamine ((2R,6R)-HNK) is administered to a female or male subject prior to a stressor.
    Type: Grant
    Filed: September 28, 2022
    Date of Patent: March 4, 2025
    Assignees: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC.
    Inventors: Christine Ann Denny, Briana Kaying Chen
  • Patent number: 12233059
    Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.
    Type: Grant
    Filed: May 21, 2024
    Date of Patent: February 25, 2025
    Assignee: Alto Neuroscience, Inc.
    Inventors: Amit Etkin, Wei Wu, Chao Wang, Nicholas Cooper, Joshua Jordan, Adam Savitz
  • Patent number: 12234220
    Abstract: Disclosed are immunomodulatory compounds, pharmaceutical compositions containing them, and methods of making and using the compounds to treat diseases and disorders characterized by aberrant protein activity that can be targeted by cereblon.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: February 25, 2025
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael Gray, Tinghu Zhang, Eric Fischer, Alyssa Verano, Zhixiang He, Guangyan Du, Katherine Donovan, Radoslaw Nowak, Jing Ting Christine Yuan, Hu Liu
  • Patent number: 12226378
    Abstract: Vaginal lubricants that have salts which are biomatched to salts that are naturally present in the vagina facilitate intercourse without toxic effects. Topical substances that have a low buffering capacity to promote fertility by providing lubricity while minimizing disturbance to the natural pH levels present during intercourse. A low buffering capacity reduces the extent to which a product interferes with natural pH and buffering capacity of fluids that are present during intercourse.
    Type: Grant
    Filed: October 26, 2022
    Date of Patent: February 18, 2025
    Assignee: VAGINAL BIOME SCIENCE, INC.
    Inventor: Wendy Strgar
  • Patent number: 12226398
    Abstract: Provided are methods of regulating proliferation and/or differentiation of keratinocytes and immune cells, more specifically to methods of treating pathologies characterized by hyperproliferative keratinocytes or inflammatory skin diseases by administration of FABP4-inhibitor.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: February 18, 2025
    Assignee: TICURE LTD.
    Inventor: Tali Garin-Shkolnik